|
1
|
Didiasova M, Schaefer L and Wygrecka M:
When place matters: Shuttling of enolase-1 across cellular
compartments. Front Cell Dev Biol. 7:612019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wold F and Ballou CE: Studies on the
enzyme enolase. II. Kinetic studies. J Biol Chem. 227:313–328.
1957. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feron O: Pyruvate into lactate and back:
from the Warburg effect to symbiotic energy fuel exchange in cancer
cells. Radiother Oncol. 92:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang J, Li H, Miao L and Ding J:
Silencing of ENO1 inhibits the proliferation, migration and
invasion of human breast cancer cells. J BUON. 25:696–701.
2020.PubMed/NCBI
|
|
6
|
Plow EF and Das R: Enolase-1 as a
plasminogen receptor. Blood. 113:5371–5372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wygrecka M, Marsh LM, Morty RE, Henneke I,
Guenther A, Lohmeyer J, Markart P and Preissner KT: Enolase-1
promotes plasminogen-mediated recruitment of monocytes to the
acutely inflamed lung. Blood. 113:5588–5598. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Principe M, Ceruti P, Shih NY,
Chattaragada MS, Rolla S, Conti L, Bestagno M, Zentilin L, Yang SH,
Migliorini P, et al: Targeting of surface alpha-enolase inhibits
the invasiveness of pancreatic cancer cells. Oncotarget.
6:11098–11113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan Z, Hu H, Zhu Y, Zhang W, Fang Q, Qiao
T, Ma T, Wang M, Huang R, Tang Q, et al: Colorectal cancer cell
intrinsic fibroblast activation protein alpha binds to Enolase1 and
activates NF-κB pathway to promote metastasis. Cell Death Dis.
12:5432021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Almaguel FA, Sanchez TW, Ortiz-Hernandez
GL and Casiano CA: Alpha-enolase: Emerging tumor-associated
antigen, cancer biomarker, and oncotherapeutic target. Front Genet.
11:6147262020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ray A, Song Y, Du T, Chauhan D and
Anderson KC: Preclinical validation of alpha-enolase (ENO1) as a
novel immunometabolic target in multiple myeloma. Oncogene.
39:2786–2796. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen ML, Yuan TT, Chuang CF, Huang YT,
Chung IC and Huang WC: A novel enolase-1 antibody targets multiple
interacting players in the tumor microenvironment of advanced
prostate cancer. Mol Cancer Ther. 21:1337–1347. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kropff MH, Bisping G, Wenning D, Volpert
S, Tchinda J, Berdel WE and Kienast J: Bortezomib in combination
with dexamethasone for relapsed multiple myeloma. Leuk Res.
29:587–590. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kumar S and Rajkumar SV: Thalidomide and
lenalidomide in the treatment of multiple myeloma. Eur J Cancer.
42:1612–1622. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lokhorst HM, Plesner T, Laubach JP, Nahi
H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo
A, et al: Targeting CD38 with daratumumab monotherapy in multiple
myeloma. N Engl J Med. 373:1207–1219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gou Y, Li F, Huo X, Hao C, Yang X, Pei Y,
Li N, Liu H and Zhu B: ENO1 monoclonal antibody inhibits invasion,
proliferation and clone formation of cervical cancer cells. Am J
Cancer Res. 11:1946–1961. 2021.PubMed/NCBI
|
|
18
|
Li HJ, Ke FY, Lin CC, Lu MY, Kuo YH, Wang
YP, Liang KH, Lin SC, Chang YH, Chen HY, et al: ENO1 promotes lung
cancer metastasis via HGFR and WNT signaling-driven
epithelial-to-mesenchymal transition. Cancer Res. 81:4094–4109.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shu X, Cao KY, Liu HQ, Yu L, Sun LX, Yang
ZH, Wu CA and Ran YL: Alpha-enolase (ENO1), identified as an
antigen to monoclonal antibody 12C7, promotes the self-renewal and
malignant phenotype of lung cancer stem cells by AMPK/mTOR pathway.
Stem Cell Res Ther. 12:1192021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo
CC, Chu PY, Hung YM, Chou SW, Yang YY, Chang GC and Liu KJ: Surface
α-enolase promotes extracellular matrix degradation and tumor
metastasis and represents a new therapeutic target. PLoS One.
8:e693542013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu L, Shi J, Cheng S, Zhu Y, Zhao X, Yang
K, Du X, Klocker H, Yang X and Zhang J: Estrogen promotes prostate
cancer cell migration via paracrine release of ENO1 from stromal
cells. Mol Endocrinol. 26:1521–1530. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujiwara S, Wada N, Kawano Y, Okuno Y,
Kikukawa Y, Endo S, Nishimura N, Ueno N, Mitsuya H and Hata H:
Lactate, a putative survival factor for myeloma cells, is
incorporated by myeloma cells through monocarboxylate transporters
1. Exp Hematol Oncol. 4:122015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samec M, Liskova A, Koklesova L, Mersakova
S, Strnadel J, Kajo K, Pec M, Zhai K, Smejkal K, Mirzaei S, et al:
Flavonoids targeting HIF-1: Implications on cancer metabolism.
Cancers (Basel). 13:1302021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qiao G, Wu A, Chen X, Tian Y and Lin X:
Enolase 1, a moonlighting protein, as a potential target for cancer
treatment. Int J Biol Sci. 17:3981–3992. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zakrzewicz D, Didiasova M, Krüger M,
Giaimo BD, Borggrefe T, Mieth M, Hocke AC, Zakrzewicz A, Schaefer
L, Preissner KT and Wygrecka M: Protein arginine methyltransferase
5 mediates enolase-1 cell surface trafficking in human lung
adenocarcinoma cells. Biochim Biophys Acta Mol Basis Dis.
1864:1816–1827. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong
SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes
cell glycolysis, growth, migration, and invasion in non-small cell
lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol.
8:222015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song Y, Luo Q, Long H, Hu Z, Que T, Zhang
X, Li Z, Wang G, Yi L, Liu Z, et al: Alpha-enolase as a potential
cancer prognostic marker promotes cell growth, migration, and
invasion in glioma. Mol Cancer. 13:652014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
El Arfani C, De Veirman K, Maes K, De
Bruyne E and Menu E: Metabolic features of multiple myeloma. Int J
Mol Sci. 19:12002018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ahmad F, Cherukuri MK and Choyke PL:
Metabolic reprogramming in prostate cancer. Br J Cancer.
125:1185–1196. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hamaguchi T, Iizuka N, Tsunedomi R,
Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima
M, Tamesa T and Oka M: Glycolysis module activated by
hypoxia-inducible factor 1alpha is related to the aggressive
phenotype of hepatocellular carcinoma. Int J Oncol. 33:725–731.
2008.PubMed/NCBI
|
|
32
|
Cippitelli M, Stabile H, Kosta A, Petillo
S, Lucantonio L, Gismondi A, Santoni A and Fionda C: Role of NF-κB
signaling in the interplay between multiple myeloma and mesenchymal
stromal cells. Int J Mol Sci. 24:18232023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wei Y, Xu H, Dai J, Peng J, Wang W, Xia L
and Zhou F: Prognostic significance of serum lactic acid, lactate
dehydrogenase, and albumin levels in patients with metastatic
colorectal cancer. Biomed Res Int. 2018:18040862018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vlachostergios PJ, Oikonomou KG, Gibilaro
E and Apergis G: Elevated lactic acid is a negative prognostic
factor in metastatic lung cancer. Cancer Biomark. 15:725–734. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Glassman PM and Balthasar JP: Mechanistic
considerations for the use of monoclonal antibodies for cancer
therapy. Cancer Biol Med. 11:20–33. 2014.PubMed/NCBI
|
|
36
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Warburg O, Wind F and Negelein E: The
Metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schwartz L, Supuran CT and Alfarouk KO:
The Warburg effect and the hallmarks of cancer. Anticancer Agents
Med Chem. 17:164–170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yu L, Chen X, Wang L and Chen S: The sweet
trap in tumors: Aerobic glycolysis and potential targets for
therapy. Oncotarget. 7:38908–38926. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Iommarini L, Porcelli AM, Gasparre G and
Kurelac I: Non-canonical mechanisms regulating hypoxia-inducible
factor 1 alpha in cancer. Front Oncol. 7:2862017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen XS, Li LY, Guan YD, Yang JM and Cheng
Y: Anticancer strategies based on the metabolic profile of tumor
cells: Therapeutic targeting of the Warburg effect. Acta Pharmacol
Sin. 37:1013–1019. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lung J, Chen KL, Hung CH, Chen CC, Hung
MS, Lin YC, Wu CY, Lee KD, Shih NY and Tsai YH: In silico-based
identification of human α-enolase inhibitors to block cancer cell
growth metabolically. Drug Des Devel Ther. 11:3281–3290. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Galluzzi L, Kepp O, Vander Heiden MG and
Kroemer G: Metabolic targets for cancer therapy. Nat Rev Drug
Discov. 12:829–846. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
de la Cruz-López KG, Castro-Muñoz LJ,
Reyes-Hernández DO, García-Carrancá A and Manzo-Merino J: Lactate
in the regulation of tumor microenvironment and therapeutic
approaches. Front Oncol. 9:11432019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Brand A, Singer K, Koehl GE, Kolitzus M,
Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K, et
al: LDHA-associated lactic acid production blunts tumor
immunosurveillance by T and NK cells. Cell Metab. 24:657–671. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Goodwin ML, Gladden LB, Nijsten MWN and
Jones KB: Lactate and cancer: Revisiting the warburg effect in an
era of lactate shuttling. Front Nutr. 1:272015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fujiwara S, Kawano Y, Yuki H, Okuno Y,
Nosaka K, Mitsuya H and Hata H: PDK1 inhibition is a novel
therapeutic target in multiple myeloma. Br J Cancer. 108:170–178.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Capello M, Ferri-Borgogno S, Riganti C,
Chattaragada MS, Principe M, Roux C, Zhou W, Petricoin EF, Cappello
P and Novelli F: Targeting the Warburg effect in cancer cells
through ENO1 knockdown rescues oxidative phosphorylation and
induces growth arrest. Oncotarget. 7:5598–5612. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Maiso P, Huynh D, Moschetta M, Sacco A,
Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC and
Ghobrial IM: Metabolic signature identifies novel targets for drug
resistance in multiple myeloma. Cancer Res. 75:2071–2082. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nakano A, Miki H, Nakamura S, Harada T,
Oda A, Amou H, Fujii S, Kagawa K, Takeuchi K, Ozaki S, et al:
Up-regulation of hexokinaseII in myeloma cells: Targeting myeloma
cells with 3-bromopyruvate. J Bioenerg Biomembr. 44:31–38. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gonias SL and Hu J: Urokinase receptor and
resistance to targeted anticancer agents. Front Pharmacol.
6:1542015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zuo J, Wang B, Long M, Gao Z, Zhang Z,
Wang H, Wang X, Li R, Dong K and Zhang H: The type 1 transmembrane
glycoprotein B7-H3 interacts with the glycolytic enzyme ENO1 to
promote malignancy and glycolysis in HeLa cells. FEBS Lett.
592:2476–2488. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Shi T, Ma Y, Cao L, Zhan S, Xu Y, Fu F,
Liu C, Zhang G, Wang Z, Wang R, et al: B7-H3 promotes aerobic
glycolysis and chemoresistance in colorectal cancer cells by
regulating HK2. Cell Death Dis. 10:3082019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ishii T, Seike T, Nakashima T, Juliger S,
Maharaj L, Soga S, Akinaga S, Cavenagh J, Joel S and Shiotsu Y:
Anti-tumor activity against multiple myeloma by combination of
KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J.
2:e682012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sanchez L, Wang Y, Siegel DS and Wang ML:
Daratumumab: A first-in-class CD38 monoclonal antibody for the
treatment of multiple myeloma. J Hematol Oncol. 9:512016.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Storti P, Bolzoni M, Donofrio G, Airoldi
I, Guasco D, Toscani D, Martella E, Lazzaretti M, Mancini C,
Agnelli L, et al: Hypoxia-inducible factor (HIF)-1α suppression in
myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis
and bone destruction. Leukemia. 27:1697–1706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
de Oliveira G, Freire PP, Cury SS, de
Moraes D, Oliveira JS, Dal-Pai-Silva M, Reis PP and Carvalho RF: An
integrated meta-analysis of secretome and proteome identify
potential biomarkers of pancreatic ductal adenocarcinoma. Cancers
(Basel). 12:7162020. View Article : Google Scholar : PubMed/NCBI
|
